English
 
 

About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Located in Shanghai and Silicon Valley, we are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $1 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

 

 

News

July 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

June 25, 2020
Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies

June 18, 2020
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

June 12, 2020
Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test

June 10, 2020
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform

June 10, 2020
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

June 4, 2020
Everest Medicines Completes US$310 Million Series C Financing

May 27, 2020
Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences

May 21, 2020
Mindstrong Announces $100M Funding Round to Scale its Virtual Mental Healthcare & Digital Symptom Measurement Offering

May 20, 2020
Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

May 11, 2020
Hummingbird Bioscience closes US$25M investment with Series B extension

May 6, 2020
GRAIL Announces $390 Million Series D Financing

January 30, 2020
Mammoth Biosciences Raises $45 Million to Build Next Generation CRISPR Products For Therapeutics and Diagnostics

January 10, 2020
ReadCoor, Inc. Announces $27 Million Series B Financing for Commercial Launch of 3D RNA, DNA, and Protein Spatial Sequencing Platform

January 9, 2020
Omniome Closes $60 Million Series C Financing to Advance Novel Genomic Sequencing Platform

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.